drugset / Trial / NCT04839744
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the comparability of TG103 injection subject to changes in the manufacturing process in Chinese healthy male subjects.
Timeline
- Start
- 2021-05-18
- Primary completion
- 2021-06-15
- Completion
- 2021-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG103 | Protein / enzyme biologic | 15 mg | Subcutaneous |
Indications
No indication recorded.